BTBelinda H Tan

Belinda H Tan

*This is an algorithmically generated author record based on publicly available information.

Belinda H Tan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Candidate Syndromic Triad of Acne Keloidalis Nuchae, Dissecting Cellulitis, and Secondary Cutis Verticis Gyrata

    by Sanusi Umar, Ochanya Ogah, Jason Yang, Belinda H Tan, Nancy Aiead, Paul K Shitabata

    Purpose: Acne keloidalis nuchae (AKN) affects the posterior hairline/nape; dissecting cellulitis of the scalp (DCS) is a suppurative scarring alopecia; and cutis verticis gyrata (CVG) describes scalp folds that may arise from chronic inflammation. This small retrospective, hypothesis-generating case series describes a clinicopathologically corroborated constellation of AKN, scalp-wide DCS, and extensive secondary CVG. Patients and Methods: At one Los Angeles hair clinic, 12 consecutive men evaluated for suspected or confirmed DCS from December 2022 through November 2024 underwent full-scalp and posterior hairline/nape examination with trichoscopy. Triad eligibility required clinicopathologically confirmed AKN, clinicopathologically confirmed DCS involving at least 3 scalp zones, and clinically extensive CVG involving at least 3 zones. Biopsy compartments were standardized, while exact sites were selected by clinician judgment using morphology and trichoscopy. Results: Three patients met prespecified criteria (age range, 30– 40 years; 2 Hispanic and 1 African American). This referral-enriched case-ascertainment observation is not a prevalence estimate. All had class II or III tumorous AKN, draining boggy nodules with scarring alopecia, and extensive cerebriform folds. Posterior hairline symptoms preceded diffuse scalp inflammation and furrowing by approximately 1– 2 years. Nuchal and scalp biopsies supported AKN and DCS, respectively; clinically normal-appearing scalp biopsies showed perifollicular infundibulo-isthmic lymphocytic inflammation with fibrosis. Conclusion: The AKN-DCS-CVG constellation may represent a candidate syndromic triad characterized by high inflammatory burden and extensive fibrotic scalp remodeling. Recognition should prompt reciprocal examination of the full scalp and posterior hairline/nape. Multicenter studies are needed to validate the constellation and define its epidemiology, chronology, and clinical outcomes.


  • Open Access

    Perifollicular Lymphocytic Inflammation and Fibrosis in Dissecting Cellulitis: Evidence of a Consistent Histopathologic Pattern

    by Sanusi Umar, Ochanya Ogah, Jason Yang, Belinda H Tan, Nancy Aiead, Paul K Shitabata

    Purpose: Dissecting cellulitis of the scalp (DCS) is a chronic, relapsing, suppurative primary cicatricial alopecia. Perifollicular infundibulo-isthmic lymphocytic inflammation and fibrosis (PIILIF) occurs in clinically normal-appearing scalp (cNAS) in other primary cicatricial alopecias but has not been systematically evaluated in DCS. Patients and Methods: In this retrospective exploratory study, we reviewed consecutive patients with clinicopathologically concordant DCS evaluated at a single Los Angeles dermatology clinic from December 2022 to November 2024. Patients underwent trichoscopy-guided 6-mm punch biopsy of cNAS and a second biopsy of an active lesion or inactive nodule. Specimens were processed with vertical and transverse sections and independently reviewed by two blinded board-certified dermatopathologists. CD4, CD8, CD117, and, when needed, α-smooth muscle actin immunostaining supported characterization. Exact tests with false-discovery-rate adjustment were exploratory. Results: Twelve men were included (mean age, 30 years; range, 21– 46 years). PIILIF was identified in all cNAS biopsies (12/12; 100%; exact 95% CI, 73.5– 100%) and all inactive nodules (3/3). Active lesions (9/9) showed suppurative inflammation and remodeling superimposed on PIILIF (infundibulo-isthmic fibrosis, 9/9; lymphocytes, 8/9), with increased neutrophilic infiltrates (9/9 vs 0/9 in matched cNAS; adjusted P< 0.001), granulation tissue (5/9 vs 0/9; adjusted P=0.035), and complete sebaceous gland loss (6/9 vs 0/9; adjusted P=0.012). Infiltrates were CD4-predominant with prominent CD117-positive mast cells. PIILIF was observed in a sideburn biopsy in one patient, and 3 patients (25%) had concurrent histologic acne keloidalis nuchae. Conclusion: In this small cohort, PIILIF was consistently observed in cNAS and inactive nodules from patients with DCS, while active lesions showed additional suppurative destruction. These findings support the hypothesis that PIILIF may represent a subclinical histopathologic component of DCS. Prospective controlled studies are needed to determine specificity, temporal sequence, and prognostic significance.


  • Open Access

    Perifollicular Inflammation and Fibrosis in Androgenetic Alopecia: Implications for Diagnosis and Treatment - A Comparative Histopathologic and Clinical Study with Normal-Appearing Scalp

    by Sanusi Umar, Belinda H Tan, Paul K Shitabata

    Introduction: Androgenetic alopecia (AGA) is traditionally regarded as a noninflammatory, androgen-driven condition. Yet clinical and histologic evidence identifies a subset of patients with perifollicular infundibulo-isthmic lymphocytic infiltrates and fibrosis (PIILIF), a histopathologic pattern resembling early primary cicatricial alopecia (PCA). This study evaluates the clinical, histologic, and immunophenotypic features of PIILIF and their diagnostic and therapeutic implications. Methods: This retrospective study of 129 AGA patients drawn from a referral center, obtained trichoscopy-guided biopsies from balding and clinically non-alopecic scalp (cNAS). Histopathologic and immunohistochemical findings were correlated with clinical features and treatment outcomes. Patients with PIILIF received multimodal therapy targeting androgenic and inflammatory pathways. The cohort, from a specialty clinic, included both typical and treatment-resistant AGA. Results: PIILIF was identified in the cNAS of 81% of patients, particularly in those aged 44 or older, with Norwood stage ≥ 5, or with prior poor response to therapy. Histology showed CD117+ mast cells, perifollicular CD4-predominant lymphocytes and fibrosis in the infundibulo-isthmic unit. Combination therapy using dihydrotestosterone blockade plus anti-inflammatory agents modeled after PCA therapies, including tetracyclines, topical calcineurin inhibitors, and select phytoactive botanicals, yielded greater improvement than standard AGA treatment regimens alone. Overall, 67% improved, and 2% had suboptimal outcomes (p < 0.0001). These findings support an AGA-PIILIF continuum that may include fibrosing alopecia in a pattern distribution. Conclusion: PIILIF represents an under‑recognized inflammatory endotype within AGA that may account for treatment resistance in some patients. Early biopsy can confirm the diagnosis, and therapy targeting hormonal and immune pathways may improve outcomes. Routine trichoscopy with a low threshold to biopsy perifollicularly abnormal units showing mild erythema, scale, or hyperpigmented collars can guide care, particularly in treatment resistant or equivocal cases. The broader systemic implications of this inflammatory signature merit further investigation. Plain Language Summary: Pattern hair loss is usually linked to hormones. Yet some people do not improve with standard treatment. We asked whether an immune type of inflammation, similar to what doctors see in scarring alopecias, might be present in these patients. We studied 129 adults with pattern hair loss. Using a magnified scalp exam, we took tiny skin samples from thinning areas and from nearby skin that looked normal. Most patients, 81%, had immune inflammation around the upper part of follicles with early scarring, even where the scalp looked normal. This differs from the mild, nonspecific inflammation sometimes seen in long-standing baldness. It was more common after age 44 and with advanced thinning. On magnified exam, a reddish ring, a darker ring in skin of color, or fine scale was common but not predictive, and redness faded with pressure. People did better when treatment targeted both hormones and this immune inflammation. The anti-inflammatory medicines were the same types used for scarring alopecias, such as tetracyclines, topical calcineurin inhibitors, and selected botanical agents, together with blockers of dihydrotestosterone. Overall, 67% improved, and 2% had a poor result. What this means is that an immune, scarring-type process can coexist with hormone-driven hair loss and may help explain treatment resistance in some patients. It also supports that, when treatment is not working or the exam is unclear, a biopsy can confirm the diagnosis and guide care. Early targeted therapy may improve outcomes.